

Samsung Biologics to launch new platforms for antibody development process

30 September 2022 | News

To provide early insight and ensure higher yield of molecules



South Korea-based Samsung Biologics, a world-leading contract development and manufacturing organization (CDMO), is launching its new proprietary development technology platforms – S-DUAL and DEVELOPICK – at this year's BioProcess International Conference and Exhibition in Boston.

S-DUAL is a high-yield bispecific antibody platform with a 99% chain-pairing success rate. Its unique asymmetrical structure reduces risks associated with chemistry, manufacturing and control (CMC), and thus ensures high binding affinity among chains to produce high titer and purity for optimized manufacturability.

DEVELOPICK is a rapid developability assessment platform that systematically screens molecules at an early development stage to identify candidates with the best potential for advancement to Investigational New Drug (IND) and Biological License Application (BLA). Requiring only 20 milligrams of material, the assessment platform enables clients to conduct a robust risk assessment for unsorted drug candidates within a month, guiding them to the path of biotherapeutic development success.